Newsfeeds - Spark Newswire

1 minute read

Evercore ISI Group Initiates Coverage On Crinetics Pharmaceuticals with Outperform Rating, Announces Price Target of $68

Today, 10:41 PM

Evercore ISI Group analyst Maneka Mirchandaney initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform rating and announces Price Target of $68.

CRNX

2 minute read

Last Week’s Notable Insider Buys: Beacon Roofing Supply, Enfusion, Nerdy And More

By Nelson Hem

Today, 10:41 PM

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near highs. Beneficial owners made some the most notable insider purchases last week. Some insiders took advantage of public offerings of shares as well.

ACHR

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:41 PM

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares climbed 356.8% to close at $45.50 on Thursday following an announcement the company will merge with Trump Media & Technology Group.

ABB

1 minute read

Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company

By Vandana Singh

Today, 10:41 PM

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) spun out a new company, Radionetics, focused solely on a burgeoning field of radiopharmaceuticals. Radiopharmaceuticals are a…

CRNX

3 minute read

News

Radionetics Oncology Emerges From Crinetics Pharmaceuticals With A Platform And Deep Pipeline Of Nonpeptide Targeted Radiopharmaceutical Drug Candidates For Precision Oncology

By Benzinga Newsdesk

Today, 10:41 PM

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel nonpeptide therapeutics for rare endocrine diseases and

CRNX

5 minute read

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

By Shanthi Rexaline

Today, 10:41 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)

ACHL

1 minute read

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept With Strong Dose-dependent Suppression Of Insulin Secretion In Phase 1 Single Ascending Dose Study

By Benzinga Newsdesk

Today, 10:41 PM

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in Glucose-stimulated and

CRNX